Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

The HARMONY study compared two doses of Akero's FGF21 mimic efruxifermin to placebo over 24 weeks in 128 adult patients with biopsy-confirmed NASH, a serious form of non-alcoholic fatty liver ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis ... (F4) due to NASH, a form of non-alcoholic fatty liver disease ...

A high-level overview of Akero Therapeutics, Inc. (AKRO) stock. View (AKRO) real-time stock price, chart, news, ... Akero raised to Buy at Bank of America after liver drug data SA News Thu, Jan. 30.

Review the current valuation for Akero Therapeutics Inc (AKRO:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Liver diseases are any diseases that affect the functioning of the liver. Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example ...

Foxa transcription factors help endow the competence to activate liver genes in development by binding to regulatory sequences in precursor endoderm and opening a local domain of chromatin ...